Cargando…
Searching for a technology-driven acute rheumatic fever test: the START study protocol
INTRODUCTION: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause o...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444258/ https://www.ncbi.nlm.nih.gov/pubmed/34526345 http://dx.doi.org/10.1136/bmjopen-2021-053720 |
_version_ | 1784568452662427648 |
---|---|
author | Ralph, Anna P Webb, Rachel Moreland, Nicole J McGregor, Reuben Bosco, Anthony Broadhurst, David Lassmann, Timo Barnett, Timothy C Benothman, Rym Yan, Jennifer Remenyi, Bo Bennett, Julie Wilson, Nigel Mayo, Mark Pearson, Glenn Kollmann, Tobias Carapetis, Jonathan R |
author_facet | Ralph, Anna P Webb, Rachel Moreland, Nicole J McGregor, Reuben Bosco, Anthony Broadhurst, David Lassmann, Timo Barnett, Timothy C Benothman, Rym Yan, Jennifer Remenyi, Bo Bennett, Julie Wilson, Nigel Mayo, Mark Pearson, Glenn Kollmann, Tobias Carapetis, Jonathan R |
author_sort | Ralph, Anna P |
collection | PubMed |
description | INTRODUCTION: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause of health inequity and premature mortality for Indigenous peoples of Australia, New Zealand and internationally. METHODS AND ANALYSIS: ‘Searching for a Technology-Driven Acute Rheumatic Fever Test’ (START) is a biomarker discovery study that aims to detect and test a biomarker signature that distinguishes ARF cases from non-ARF, and use systems biology and serology to better understand ARF pathogenesis. Eligible participants with ARF diagnosed by an expert clinical panel according to the 2015 Revised Jones Criteria, aged 5–30 years, will be recruited from three hospitals in Australia and New Zealand. Age, sex and ethnicity-matched individuals who are healthy or have non-ARF acute diagnoses or RHD, will be recruited as controls. In the discovery cohort, blood samples collected at baseline, and during convalescence in a subset, will be interrogated by comprehensive profiling to generate possible diagnostic biomarker signatures. A biomarker validation cohort will subsequently be used to test promising combinations of biomarkers. By defining the first biomarker signatures able to discriminate between ARF and other clinical conditions, the START study has the potential to transform the approach to ARF diagnosis and RHD prevention. ETHICS AND DISSEMINATION: The study has approval from the Northern Territory Department of Health and Menzies School of Health Research ethics committee and the New Zealand Health and Disability Ethics Committee. It will be conducted according to ethical standards for research involving Indigenous Australians and New Zealand Māori and Pacific Peoples. Indigenous investigators and governance groups will provide oversight of study processes and advise on cultural matters. |
format | Online Article Text |
id | pubmed-8444258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84442582021-10-01 Searching for a technology-driven acute rheumatic fever test: the START study protocol Ralph, Anna P Webb, Rachel Moreland, Nicole J McGregor, Reuben Bosco, Anthony Broadhurst, David Lassmann, Timo Barnett, Timothy C Benothman, Rym Yan, Jennifer Remenyi, Bo Bennett, Julie Wilson, Nigel Mayo, Mark Pearson, Glenn Kollmann, Tobias Carapetis, Jonathan R BMJ Open Global Health INTRODUCTION: The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus. It is the precursor to rheumatic heart disease (RHD), a leading cause of health inequity and premature mortality for Indigenous peoples of Australia, New Zealand and internationally. METHODS AND ANALYSIS: ‘Searching for a Technology-Driven Acute Rheumatic Fever Test’ (START) is a biomarker discovery study that aims to detect and test a biomarker signature that distinguishes ARF cases from non-ARF, and use systems biology and serology to better understand ARF pathogenesis. Eligible participants with ARF diagnosed by an expert clinical panel according to the 2015 Revised Jones Criteria, aged 5–30 years, will be recruited from three hospitals in Australia and New Zealand. Age, sex and ethnicity-matched individuals who are healthy or have non-ARF acute diagnoses or RHD, will be recruited as controls. In the discovery cohort, blood samples collected at baseline, and during convalescence in a subset, will be interrogated by comprehensive profiling to generate possible diagnostic biomarker signatures. A biomarker validation cohort will subsequently be used to test promising combinations of biomarkers. By defining the first biomarker signatures able to discriminate between ARF and other clinical conditions, the START study has the potential to transform the approach to ARF diagnosis and RHD prevention. ETHICS AND DISSEMINATION: The study has approval from the Northern Territory Department of Health and Menzies School of Health Research ethics committee and the New Zealand Health and Disability Ethics Committee. It will be conducted according to ethical standards for research involving Indigenous Australians and New Zealand Māori and Pacific Peoples. Indigenous investigators and governance groups will provide oversight of study processes and advise on cultural matters. BMJ Publishing Group 2021-09-15 /pmc/articles/PMC8444258/ /pubmed/34526345 http://dx.doi.org/10.1136/bmjopen-2021-053720 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Global Health Ralph, Anna P Webb, Rachel Moreland, Nicole J McGregor, Reuben Bosco, Anthony Broadhurst, David Lassmann, Timo Barnett, Timothy C Benothman, Rym Yan, Jennifer Remenyi, Bo Bennett, Julie Wilson, Nigel Mayo, Mark Pearson, Glenn Kollmann, Tobias Carapetis, Jonathan R Searching for a technology-driven acute rheumatic fever test: the START study protocol |
title | Searching for a technology-driven acute rheumatic fever test: the START study protocol |
title_full | Searching for a technology-driven acute rheumatic fever test: the START study protocol |
title_fullStr | Searching for a technology-driven acute rheumatic fever test: the START study protocol |
title_full_unstemmed | Searching for a technology-driven acute rheumatic fever test: the START study protocol |
title_short | Searching for a technology-driven acute rheumatic fever test: the START study protocol |
title_sort | searching for a technology-driven acute rheumatic fever test: the start study protocol |
topic | Global Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444258/ https://www.ncbi.nlm.nih.gov/pubmed/34526345 http://dx.doi.org/10.1136/bmjopen-2021-053720 |
work_keys_str_mv | AT ralphannap searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT webbrachel searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT morelandnicolej searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT mcgregorreuben searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT boscoanthony searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT broadhurstdavid searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT lassmanntimo searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT barnetttimothyc searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT benothmanrym searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT yanjennifer searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT remenyibo searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT bennettjulie searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT wilsonnigel searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT mayomark searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT pearsonglenn searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT kollmanntobias searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol AT carapetisjonathanr searchingforatechnologydrivenacuterheumaticfevertestthestartstudyprotocol |